SEGLENTIS is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Kowa Pharmaceuticals America, Inc.. The primary component is Celecoxib; Tramadol Hydrochloride.
Product ID | 66869-564_cf2c8436-a9f4-473c-e053-2a95a90a1123 |
NDC | 66869-564 |
Product Type | Human Prescription Drug |
Proprietary Name | SEGLENTIS |
Generic Name | Celecoxib And Tramadol Hydrochloride |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2022-01-01 |
Marketing Category | NDA / |
Application Number | NDA213426 |
Labeler Name | Kowa Pharmaceuticals America, Inc. |
Substance Name | CELECOXIB; TRAMADOL HYDROCHLORIDE |
Active Ingredient Strength | 56 mg/1; mg/1 |
Pharm Classes | Cyclooxygenase Inhibitors [MoA],Anti-Inflammatory Agents, Non-Steroidal [CS],Nonsteroidal Anti-inflammatory Drug [EPC],Full Opioid Agonists [MoA],Opioid Agonist [EPC] |
DEA Schedule | CIV |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2022-01-01 |
NDC Exclude Flag | N |
Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
SEGLENTIS 87827471 not registered Live/Pending |
ESTEVE PHARMACEUTICALS, S.A. 2018-03-09 |